Misrepresented Uncertainty in Tylenol Use and Autism Spectrum Disorder: A Case Study in the Politicization of Prenatal Care

Abstract

In September 2025, the executive branch of the United States government intervened directly in clinical pharmacology and prenatal care guidelines, creating an unprecedented schism between federal political leadership and established medical consensus. President Donald J. Trump, supported by Health and Human Services Secretary Robert F. Kennedy Jr., issued a public advisory urging pregnant women to avoid acetaminophen (paracetamol)—the global standard of care for prenatal pain and fever management—citing a causal link to Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). This report provides an exhaustive examination of this controversy, analyzing the divergence between political rhetoric and the scientific record. It deconstructs the epidemiological evidence regarding prenatal acetaminophen exposure, exploring the critical role of confounding by indication and familial genetics. Furthermore, it details the biological plausibility arguments concerning oxidative stress and glutathione depletion, contrasting them with the findings of the federal Multidistrict Litigation (MDL) In re Acetaminophen, where judicial gatekeeping under the Daubert standard rigorously excluded the very scientific theories promoted by the administration. The analysis concludes that the 2025 advisory represents a misrepresentation of scientific uncertainty, potentially endangering maternal and fetal health by discouraging the treatment of teratogenic fevers based on disproven legal hypotheses.

I. Introduction: The Collision of Politics and Pediatrics

1.1 The September 2025 Directive

On September 22, 2025, the Roosevelt Room of the White House became the stage for a radical departure in public health communication. President Trump and HHS Secretary Kennedy unveiled a series of "bold new actions" aimed at curbing what they termed the "autism epidemic," a phenomenon they claimed had surged nearly 400% since the turn of the millennium.¹ Central to this initiative was a specific, actionable warning: pregnant women should avoid acetaminophen, the active ingredient in Tylenol and hundreds of other over-the-counter medications, unless "absolutely necessary".²

The advisory was not merely a suggestion of caution; it was framed as a revelation of suppressed truth. The administration leveraged the platform to bypass traditional regulatory filters, directly addressing the American public with claims that the ubiquitous painkiller was a primary driver of neurodevelopmental disorders. This announcement was coupled with controversial advice regarding vaccination schedules—urging the "breaking up" of the MMR vaccine—and the promotion of a specific pharmaceutical agent, leucovorin, as a therapeutic intervention for autism.³

1.2 The Divergence from Medical Consensus

The immediate aftermath of the announcement was a cacophony of conflicting guidance. While the White House declared acetaminophen a risk, the world’s leading medical and public health bodies maintained the opposite. The American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the World Health Organization (WHO) reiterated their longstanding positions: acetaminophen remains the only safe analgesic and antipyretic for use during pregnancy.⁵

This divergence placed pregnant patients in a precarious dilemma. On one side stood the highest political office in the land, asserting that a common drug could permanently damage their unborn child's brain. On the other stood their physicians and global health data, warning that untreated fever and pain posed tangible, proven risks to the fetus. To understand how the United States arrived at this moment of epistemological crisis, one must peel back the layers of toxic tort litigation, observational epidemiology, and biological theory that underpin the "Tylenol-Autism" hypothesis.

II. The Molecule in Question: Acetaminophen in Obstetrics

2.1 The Historical Context of Safety

Acetaminophen (known as paracetamol in Europe and most of the world) has occupied a unique niche in obstetric medicine for over half a century. Its dominance is not necessarily due to superior efficacy compared to other analgesics, but rather the severe safety profiles of the alternatives.

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil/Motrin) and naproxen (Aleve), are potent inhibitors of prostaglandin synthesis. While effective for pain, their use during pregnancy—particularly in the third trimester—is contraindicated. NSAIDs can cause the premature closure of the ductus arteriosus, a vital fetal blood vessel that bypasses the fluid-filled lungs to route oxygenated blood to the body. Premature closure can lead to pulmonary hypertension and heart failure in the neonate. Additionally, NSAIDs are linked to fetal renal toxicity and oligohydramnios (low amniotic fluid).⁷

Opioids, while effective analgesics, carry the risk of neonatal abstinence syndrome (withdrawal) and maternal addiction. Aspirin is generally avoided due to bleeding risks, except in low doses for pre-eclampsia prevention.

Consequently, acetaminophen became the default, "safe" option. It operates through a different mechanism—believed to involve the inhibition of cyclooxygenase (COX) enzymes in the central nervous system and interaction with the endocannabinoid system—that avoids the peripheral side effects of NSAIDs. It is estimated that over 50% of pregnant women worldwide use acetaminophen at some point during gestation.⁸ This ubiquity, however, makes it a prime candidate for epidemiological scrutiny: if nearly everyone takes it, and autism rates are rising, statistical correlations are inevitable, whether causal or not.

2.2 The Rise of the "Autism Epidemic" Narrative

The administration's framing of an "autism epidemic" relies on the rising prevalence of ASD diagnoses, now affecting approximately 1 in 31 American children.¹ The scientific consensus attributes much of this rise to broadened diagnostic criteria, increased awareness, and better screening, rather than a true increase in incidence. However, the political narrative—echoing the theories of the litigation industry—posits an environmental toxicant as the culprit. Acetaminophen, introduced and popularized in the same decades that autism diagnoses began to climb, provided a convenient temporal correlation for this hypothesis.

III. The Epidemiological Evidence: Signal, Noise, and Bias

The core of the anti-acetaminophen argument rests on observational epidemiology. Over the last decade, several large cohort studies have reported an association between maternal acetaminophen use and adverse neurodevelopmental outcomes in offspring.

3.1 The Positive Associations

Studies such as the Danish National Birth Cohort and the Nurses’ Health Study II have generated the data points most frequently cited by the Trump administration and plaintiffs' attorneys.

• The Danish National Birth Cohort: A massive study following over 64,000 mother-child pairs. It found that children of mothers who used acetaminophen during pregnancy had a higher risk of being diagnosed with hyperkinetic disorders (a proxy for ADHD) and ASD. The risk appeared to increase with the duration of use; mothers who used the drug for more than 20 weeks had a risk almost double that of non-users.⁹

• The Nurses’ Health Study II: A US-based study of nearly 9,000 children, which found a similar association between maternal use and subsequent ADHD diagnoses.⁷

• The Navigation Guide Review (2025): A systematic review applied the "Navigation Guide" methodology to 46 studies. It concluded that 27 studies showed positive associations between prenatal exposure and neurodevelopmental disorders, while only 9 were null and 4 were negative (protective). The authors of this review argued that the "majority of studies" supported a link, urging immediate precautionary advice.⁸

Proponents argue that these studies, due to their large sample sizes, provide a "strong signal" that warrants action. They point to the "consistency" of the finding across different populations as evidence of causality.

3.2 The Fundamental Flaw: Confounding by Indication

However, the leap from "association" to "causation" in these studies is treacherous due to a methodological pitfall known as confounding by indication.

In observational studies, researchers do not control who takes the drug; the patients do. Pregnant women do not take acetaminophen recreationally. They take it because they are suffering from specific medical indications:

1. Fever (Pyrexia): Often caused by viral or bacterial infections (influenza, chorioamnionitis, urinary tract infections).

2. Pain / Inflammation: Headaches, musculoskeletal pain, autoimmune flare-ups.

This creates a critical problem for causal inference. We know from decades of independent research that maternal inflammation and fever are themselves teratogenic.

• Fever Effect: High maternal temperature can disrupt neuronal migration and cell proliferation in the developing fetal brain.

• Immune Activation: Infections trigger the release of cytokines (like Interleukin-6 and Tumor Necrosis Factor-alpha). These molecules can cross the placenta and induce neuro-inflammation in the fetus, a known pathway for increasing the risk of ASD and schizophrenia.¹⁰

Therefore, when a study finds that "Children of mothers who took Tylenol have more autism," it is statistically impossible—without rigorous controls—to determine if the autism was caused by the Tylenol or by the fever/infection that the mother treated with Tylenol. If the infection causes the autism, Tylenol is merely an innocent bystander, or "confounder."

3.3 The Failure to Control for Genetics

Beyond the indication for use, there is the issue of familial confounding. Genetic factors play a massive role in neurodevelopmental disorders; the heritability of autism is estimated at 60-80%. Conditions that cause chronic pain (like migraines or autoimmune disorders) often have genetic components that may overlap with neurodevelopmental susceptibility. If a mother has a genetic predisposition to conditions requiring pain relief, and also carries genes associated with ADHD/ASD, the association between the drug and the child's diagnosis is genetic, not pharmacologic.¹²

3.4 The "Gold Standard" Rebuttal: Sibling Comparisons

To isolate the drug's effect from these confounding factors (genetics and stable environmental traits), epidemiologists use sibling control designs. In these studies, researchers compare two children born to the same mother: one exposed to acetaminophen during pregnancy, and one not.

Because siblings share approximately 50% of their DNA and the same maternal socioeconomic environment, this design controls for "unmeasured familial confounders" far better than comparing unrelated strangers.

• The Swedish Sibling Study (2024): A landmark analysis of 2.5 million children born in Sweden. In the initial "population" analysis (comparing strangers), the study replicated the usual finding: a slight increase in autism risk for Tylenol users. However, when the researchers switched to the sibling comparison, the association vanished. There was no difference in autism risk between the exposed sibling and the unexposed sibling.³

• The Japanese Cohort (2025): A study of 200,000 pregnancies yielded identical results. The population-level association disappeared entirely when sibling controls were applied.¹³

These findings strongly suggest that the "link" observed in earlier studies was a mirage—an artifact of genetic and environmental confounding, not a toxic effect of the drug itself.

IV. The Biological Plausibility Debate

Despite the epidemiological evidence weakening under sibling-control scrutiny, proponents of the causal link argue that there are plausible biological mechanisms by which acetaminophen could damage the fetal brain. These arguments are central to the "toxicity" narrative promoted by the administration and the plaintiffs' experts.

4.1 The Mechanism of Toxicity: Glutathione Depletion

The primary biological hypothesis involves glutathione, the body's master antioxidant.

1. Metabolic Pathway: Acetaminophen is metabolized in the liver. While most is processed safely, a small fraction (via the CYP2E1 enzyme pathway) is converted into a highly reactive, toxic metabolite called N-acetyl-p-benzoquinone imine (NAPQI).¹⁴

2. Detoxification: In a healthy individual, NAPQI is instantly neutralized by binding to glutathione.

3. The Danger Zone: If glutathione levels are depleted, or if NAPQI production is excessive (as in an overdose), the toxic metabolite accumulates. It binds to cellular proteins and mitochondrial DNA, causing oxidative stress and cell death.¹⁵

The Theory: Proponents argue that the fetus is in a state of "oxidative vulnerability." They claim that even therapeutic doses of acetaminophen can deplete the limited fetal supply of glutathione. This temporary depletion allows oxidative stress to damage developing neurons, disrupting the "pruning" and organization of brain connections, ultimately leading to the "wiring" differences characteristic of ASD and ADHD.¹⁴

The Scientific Reality: While this mechanism is well-established for hepatic necrosis in overdose scenarios, its application to neurodevelopment at therapeutic doses is speculative.

• Dose-Response: Toxicology is defined by the principle "the dose makes the poison." There is no robust evidence in humans that standard therapeutic doses (e.g., 650mg or 1000mg) deplete fetal glutathione to a level sufficient to cause neuronal injury.¹⁸

• Redundancy: The body has robust mechanisms to regenerate glutathione. The idea that a transient drop in antioxidant capacity causes permanent structural brain changes remains a hypothesis (plausible in high-dose animal models) rather than a proven clinical reality in humans.

4.2 Endocrine Disruption and Cannabinoids

A secondary hypothesis posits that acetaminophen acts as an endocrine disruptor.

• Testosterone Suppression: Some rodent studies suggest acetaminophen exposure can reduce fetal testosterone production. Since sex hormones play a role in brain masculinization and development, reduced testosterone is theorized to alter neurodevelopmental trajectories.¹⁷

• Endocannabinoid System: Acetaminophen’s analgesic effect involves the endocannabinoid system (specifically the degradation of anandamide). Since this system is also involved in neuronal migration during fetal development, critics argue that interfering with it pharmacologically could "scramble" the developing brain's architecture.⁸

While these pathways exist in animal models, the translation to human pathology is fraught with uncertainty. The MDL court specifically criticized experts for extrapolating these theoretical pathways to human causation without sufficient bridging evidence.

V. The Legal Battlefield: In re Acetaminophen

The scientific debate over Tylenol and autism did not stay in the laboratory; it moved to the federal courts. The resulting litigation, In re Acetaminophen – ASD-ADHD Products Liability Litigation (MDL No. 3043), serves as a critical independent audit of the scientific evidence.

5.1 The Multidistrict Litigation (MDL) Process

By 2022, hundreds of lawsuits had been filed against Johnson & Johnson (Tylenol) and retailers like Walmart and CVS, alleging "failure to warn." These cases were consolidated in the Southern District of New York under Senior Judge Denise Cote. The plaintiffs' central claim was that the manufacturers knew the science showed a link to autism but failed to update the warning label.¹⁹

5.2 The Daubert Standard: Gatekeeping Junk Science

In federal court, scientific testimony is governed by Federal Rule of Evidence 702 and the Supreme Court's Daubert standard. Judges must act as "gatekeepers" to ensure that expert testimony is reliable, based on sound methodology, and relevant. It is not enough for an expert to be credentialed; their methods must be scientific.²¹

Judge Cote's application of Daubert in this MDL was rigorous and devastating to the plaintiffs' case.

5.3 The Rejection of "Transdiagnostic" Analysis

One of the plaintiffs' key experts, Dr. Andrea Baccarelli, attempted to support the causation argument using a "transdiagnostic" analysis. He argued that instead of looking for a link to ASD or ADHD specifically, the court should look at "neurodevelopmental toxicity" as a broad category.

Judge Cote rejected this methodology as fundamentally flawed. She noted that ASD and ADHD are distinct diagnoses with different symptomologies. By lumping them together, the expert was able to "smooth over" the inconsistencies in the data. If a study showed a link to ADHD but not Autism, he counted it as evidence for "neurodevelopmental damage." The court ruled that this approach was results-oriented—designed to "obfuscate the weakness" of the evidence rather than enlighten the jury.²²

5.4 The "Cherry-Picking" Critique

The court also dismantled the experts' use of the Bradford Hill Criteria (the standard framework for inferring causality). The judge found that experts like Dr. Robert Cabrera engaged in systemic "cherry-picking." They cited studies with positive associations (like the Danish cohort) while ignoring or dismissing high-quality studies with null results (like the sibling studies) without valid scientific justification. The court ruled that a methodology that ignores inconvenient data is not "reliable science" under Rule 702.²¹

5.5 The Exclusion of Dr. Ness (July 2024)

After the initial slate of experts was excluded in late 2023, plaintiffs attempted to introduce Dr. Roberta Ness to salvage the case. In July 2024, Judge Cote excluded her testimony as well. The opinion was scathing. It noted that Dr. Ness, despite being an epidemiologist, demonstrated a lack of familiarity with the clinical realities of ADHD. In her deposition, she was unable to explain her proposed biological mechanism without reading directly from her notes. The court found that she had misrepresented the Baker 2020 study, claiming it used MRI validation for ADHD when it did not. This lack of "intellectual rigor" led to her disqualification.²⁰

5.6 Summary of Judicial Findings

The court's dismissal of the science was comprehensive. Judge Cote concluded that "there is no generally accepted scientific conclusion that in utero exposure to acetaminophen causes either ASD or ADHD".²³ This judicial finding stands in stark contrast to the Trump administration's assertion of "growing evidence."

VI. The Politics of Leucovorin and Vaccine Skepticism

The September 2025 announcement was not limited to attacking Tylenol; it also promoted specific alternatives and revived older controversies.

6.1 The Leucovorin "Cure" Narrative

The administration promoted Leucovorin (folinic acid) as a breakthrough treatment for autism. Leucovorin is a reduced form of folate used clinically to rescue healthy cells from the toxic effects of methotrexate chemotherapy.

The scientific basis for its use in autism is tied to a rare condition called Cerebral Folate Deficiency (CFD). In CFD, autoantibodies block the folate receptor (FRα), preventing folate from entering the brain. This causes seizures and developmental delays. Leucovorin can bypass this blockade (using the Reduced Folate Carrier, RFC) and restore brain folate levels.²⁶

The Misrepresentation: While Leucovorin treats CFD, CFD is not the cause of the vast majority of autism cases. The administration engaged in a "Motte and Bailey" fallacy: using the specific efficacy of Leucovorin for CFD (the defensible Motte) to imply it is a general treatment for Autism (the indefensible Bailey). Experts warned that promoting it as a general autism therapeutic could lead to shortages for cancer patients and expose children to side effects like agitation, aggression, and gastrointestinal distress without benefit.²⁸

6.2 Reviving Vaccine Skepticism

The President also advised parents to "break up" the MMR vaccine into separate shots, explicitly linking this advice to autism prevention.² This claim originates from the discredited work of Andrew Wakefield in the late 1990s. Multiple massive studies and reviews by the Institute of Medicine have confirmed that vaccines, and the MMR schedule specifically, do not cause autism. By linking the Tylenol warning to vaccine skepticism, the administration signaled that its advisory was rooted in the ideology of the "medical freedom" movement rather than mainstream science.³

VII. Conclusion: The Cost of Misinformation

The controversy surrounding acetaminophen and autism is a case study in the dangers of politicizing scientific uncertainty.

The Scientific Reality: The evidence linking acetaminophen to autism is weak, inconsistent, and heavily confounded by the indications for use (fever and inflammation). When rigorous methods like sibling controls are used, the association disappears.

The Legal Reality: The federal courts, applying the rigorous Daubert standard, have rejected the plaintiffs' experts for relying on cherry-picked data and flawed methodologies like transdiagnostic analysis.

The Political Reality: The 2025 Trump administration advisory ignores both the nuanced science and the judicial findings. By declaring Tylenol "unsafe," the administration has prioritized a populist narrative over public health data.

The Public Health Consequence: The most immediate danger is that pregnant women will stop treating fevers. Maternal fever is a known, potent teratogen. It causes neural tube defects and cardiac malformations. If women fear Tylenol (the only safe option) and avoid treatment, the result will not be a decrease in autism, but an increase in preventable birth defects and fetal injury. The advisory replaces a theoretical, unproven risk with a tangible, well-documented harm.

Summary of Key Findings

Domain	Finding	Key Evidence/Source
Epidemiology	Weak/Null. Positive associations in observational studies disappear when sibling controls are used.	Swedish Sibling Study (Ahlqvist et al.) 3
Mechanism	Speculative. Glutathione depletion theory is biologically plausible in overdose but unproven at therapeutic doses.	Toxicity Reviews 14
Litigation	Excluded. Experts excluded for "cherry-picking" and "transdiagnostic" flaws.	In re Acetaminophen MDL Rulings 9
Policy	Contraindicated. ACOG, FDA, WHO, EMA all recommend Tylenol as safe/necessary for fever.	ACOG/WHO Statements 5
Administration	Misleading. Conflates rare CFD treatment (Leucovorin) with general Autism cure; promotes vaccine myths.	Sept 2025 Briefing 1

VIII. Appendix: Detailed Analysis of Key Studies

A.1 The Navigation Guide Systematic Review (2025)

• Methodology: This review applied the UCSF Navigation Guide systematic review methodology to environmental health data.

• Findings: Identified 46 studies. 27 positive, 9 null, 4 negative.

• Critique: The review focused on "hazard identification" based on the number of positive studies rather than the quality of the control for confounding. It heavily weighted observational data that lacked sibling controls. The authors admitted substantial heterogeneity prevented a quantitative meta-analysis.⁸

A.2 The Swedish Sibling Control Study (Ahlqvist et al.)

• Cohort: 2.5 million children born 1995–2019.

• Design: Compared rates of ASD/ADHD in children exposed vs. unexposed. Then compared siblings discordant for exposure.

• Result: The crude model showed a Hazard Ratio (HR) of ~1.15 for autism. The sibling control model showed an HR of ~0.98 (crossing 1.0, indicating no effect).

• Implication: The "Tylenol Effect" is actually a "Family Effect" (genetics or environment).³

A.3 The Baker 2020 Controversy (Legal)

• Context: Used by Plaintiff Expert Dr. Roberta Ness to argue that acetaminophen changes brain structure.

• The Flaw: Dr. Ness claimed this study used MRI to validate ADHD diagnoses in the children.

• The Reality: The study did not measure ADHD in the children with MRI. Dr. Ness was forced to admit this error during deposition. This misrepresentation was a key factor in her exclusion from the MDL.²⁰

A.4 Mechanism of Action: Leucovorin

• Folate Receptor Alpha (FRα): The primary transporter of folate into the cerebrospinal fluid.

• Reduced Folate Carrier (RFC): A secondary transporter with lower affinity for folate, but high affinity for folinic acid (Leucovorin).

• Therapeutic Rationale: In children with FRα antibodies (CFD), the primary door is locked. Leucovorin uses the secondary door (RFC) to get folate into the brain.

• Limitations: This mechanism is irrelevant for autistic children who do not have CFD or folate transport defects. High doses can mask Vitamin B12 deficiency (pernicious anemia) leading to neurological damage.²⁶

Works cited

1. President Trump, Secretary Kennedy Announce Bold Actions to Tackle Autism Epidemic, accessed January 8, 2026, https://www.hhs.gov/press-room/hhs-trump-kennedy-autism-initiatives-leucovorin-tylenol-research-2025.html

2. Is Trump’s advice on avoiding Tylenol scientifically backed? Here's what medical organizations say, accessed January 8, 2026, https://www.hindustantimes.com/world-news/us-news/is-trump-s-advice-on-avoiding-tylenol-scientifically-backed-heres-what-medical-organizations-say-101767658786715.html

3. Trump's claims on Tylenol (paracetamol), vaccines, and autism—what's the truth? | The BMJ, accessed January 8, 2026, https://www.bmj.com/content/390/bmj.r2025

4. ASF Statement on White House Announcement on Autism, accessed January 8, 2026, https://autismsciencefoundation.org/press_releases/asf-statement-wh-briefing/

5. Much ado over acetaminophen | Annals of Internal Medicine - ACP Journals, accessed January 8, 2026, https://www.acpjournals.org/doi/10.7326/ANNALS-25-05214-IM

6. WHO statement on autism-related issues - World Health Organization (WHO), accessed January 8, 2026, https://www.who.int/news/item/24-09-2025-who-statement-on-autism-related-issues

7. 2025 Dec 08 (1743): Prenatal Acetaminophen Use and Autism - The Medical Letter, accessed January 8, 2026, https://secure.medicalletter.org/system/files/private/TML-article-1743a.pdf

8. Evaluation of the evidence on acetaminophen use and neurodevelopmental disorders using the Navigation Guide methodology - PMC - PubMed Central, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12351903/

9. Tylenol Autism Lawsuit - Updated January 2024 - The Lanier Law Firm, accessed January 8, 2026, https://www.lanierlawfirm.com/pharmaceutical-liability/tylenol-autism-lawsuit/

10. Associations of prenatal or infant exposure to acetaminophen or ibuprofen with mid-childhood executive function and behavoiur - NIH, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7170759/

11. Use of Acetaminophen (Paracetamol) During Pregnancy and the Risk of Autism Spectrum Disorder in the Offspring - Psychiatrist.com, accessed January 8, 2026, https://www.psychiatrist.com/jcp/acetaminophen-paracetamol-during-pregnancy-risk-autism/

12. Autism and Acetaminophen Use during Pregnancy: Does Science Support the Claim of a Link? | Womble Bond Dickinson, accessed January 8, 2026, https://www.womblebonddickinson.com/us/insights/blogs/autism-and-acetaminophen-use-during-pregnancy-does-science-support-claim-link

13. Understanding the Evidence on Pregnancy, Tylenol, and Autism, accessed January 8, 2026, https://publichealth.jhu.edu/2025/the-evidence-on-tylenol-and-autism

14. Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy - PMC - NIH, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10915458/

15. Prenatal Acetaminophen Exposure and its Associated Risk for Attention Deficit Hyperactivity Disorder - PMC - NIH, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11820131/

16. Glutathione depletion and oxidative stress - PubMed, accessed January 8, 2026, https://pubmed.ncbi.nlm.nih.gov/12217624/

17. The Science Behind Tylenol Use During Pregnancy and Autism | Lawsuit Legal News, accessed January 8, 2026, https://lawsuitlegalnews.com/news/science-behind-tylenol-and-autism/

18. Effects of Acetaminophen on Preimplantation Embryo Glutathione Concentration and Development in Vivo and in Vitro | Toxicological Sciences | Oxford Academic, accessed January 8, 2026, https://academic.oup.com/toxsci/article/56/1/150/1646073

19. In re Acetaminophen – ASD-ADHD Products Liability Litigation - US District Court for the Southern District of New York, accessed January 8, 2026, https://www.nysd.uscourts.gov/MDL/22md3043

20. UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ..., accessed January 8, 2026, https://www.nysd.uscourts.gov/sites/default/files/pdf/MDL/22mc3043/22md3043%202nd%20Daubert%20Opinion.pdf

21. In re: Acetaminophen - ASD-ADHD Products Liability Litigation, No. 1:2022mc03043 - Document 99 (S.D.N.Y. 2023) - Justia Law, accessed January 8, 2026, https://law.justia.com/cases/federal/district-courts/new-york/nysdce/1:2022mc03043/588200/99/

22. Acetaminophen MDL: Judge Excludes All of Plaintiffs' Causation Experts Pursuant to Newly-Amended FRE Rule 702 - Foley & Lardner LLP, accessed January 8, 2026, https://www.foley.com/insights/publications/2024/01/acetaminophen-mdl-fre-rule-702/

23. Trio of Tylenol Product-Liability Opinions Exemplifies Effective Judicial Gatekeeping, accessed January 8, 2026, https://www.winston.com/en/blogs-and-podcasts/product-liability-and-mass-torts-digest/trio-of-tylenol-product-liability-opinions-exemplifies-effective-judicial-gatekeeping

24. Conflicts of Interest - Schachtman Law, accessed January 8, 2026, https://schachtmanlaw.com/category/conflicts-of-interest/

25. accessed January 8, 2026, https://www.lawsuit-information-center.com/tylenol-autism-lawsuit.html#:~:text=In%20a%20148%2Dpage%20ruling,rendering%20the%20claims%20legally%20untenable.

26. Autism Announcement Fact Sheet | HHS.gov, accessed January 8, 2026, https://www.hhs.gov/press-room/autism-announcement-fact-sheet.html

27. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis - PMC - PubMed Central, accessed January 8, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8622150/

28. Exclusive: The 23 studies the FDA based its expanded leucovorin label on | The Transmitter, accessed January 8, 2026, https://www.thetransmitter.org/spectrum/exclusive-the-23-studies-the-fda-based-its-expanded-leucovorin-label-on/

29. Frequently Asked Questions (FAQs) for Pediatricians and other Prescribing Pediatric Clinicians: Leucovorin Use in Autism and Cerebral Folate Deficiency - AAP, accessed January 8, 2026, https://www.aap.org/en/patient-care/autism/use-of-leucovorin-in-autistic-pediatric-patients/frequently-asked-questions-faqs-for-pediatricians-and-other-prescribing-pediatric-clinicians/

30. Mental Health: Leucovorin and Autism: What Pediatricians Should Know - Children's Mercy, accessed January 8, 2026, https://www.childrensmercy.org/health-care-providers/refer-or-manage-a-patient/connect-with-childrens-mercy/newsletter-the-link/the-link-2025/the-link---october-2025/mental-health-leucovorin-and-autism-what-pediatricians-should-know/

31. FDA Takes Action to Make a Treatment Available for Autism Symptoms, accessed January 8, 2026, https://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms